Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum

T. Nakahara, T. Kuroki, E. Ohta, T. Kajihata, H. Yamada, M. Yamanaka, K. Hashimoto, T. Tsutsumi, M. Hirano, H. Uchimura

研究成果: ジャーナルへの寄稿記事

12 引用 (Scopus)

抄録

We previously reported that haloperidol, a dopamine-D2 receptor antagonist, induced striatal expression of parkin gene, which mutations cause autosomal recessive juvenile parkinsonism. Because of an involvement of the parkin gene defect in selective degeneration of dopaminergic neurons, we herein examined the effect of the neurotoxic dose of methamphetamine (METH; 40mg/kg, i.p.) on gene expression of parkin and its substrate Pael-receptor (R) in the dopamine-rich areas of the rat brain, using reverse transcription-polymerase chain reaction. parkin mRNA levels in the striatum, but not in other regions, decreased at 1 and 2h and returned to the pre-drug basal levels at 4h after METH administration. METH also decreased Pael-R mRNA levels in the striatum and substantia nigra within 2h after METH, while haloperidol (2mg/kg, s.c.) increased Pael-R mRNA levels in the substantia nigra at 2h after administration. These results suggest that temporary suppression of gene expression of parkin and Pael-R may be associated with the METH-induced dopaminergic neurotoxicity. Taken together with our previous report, dopaminergic modulation of the expression of parkin and Pael-R genes in the nigro-striatal pathway may have significant implication for pathophysiology and treatment of parkinson disease.

元の言語英語
ページ(範囲)213-219
ページ数7
ジャーナルParkinsonism and Related Disorders
9
発行部数4
DOI
出版物ステータス出版済み - 3 1 2003

Fingerprint

Methamphetamine
Corpus Striatum
Substantia Nigra
Haloperidol
Gene Expression
Messenger RNA
vpr Genes
Dopaminergic Neurons
Parkinsonian Disorders
Reverse Transcription
Parkinson Disease
Dopamine
Polymerase Chain Reaction
Mutation
Brain
Pharmaceutical Preparations
Genes

All Science Journal Classification (ASJC) codes

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

これを引用

Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum. / Nakahara, T.; Kuroki, T.; Ohta, E.; Kajihata, T.; Yamada, H.; Yamanaka, M.; Hashimoto, K.; Tsutsumi, T.; Hirano, M.; Uchimura, H.

:: Parkinsonism and Related Disorders, 巻 9, 番号 4, 01.03.2003, p. 213-219.

研究成果: ジャーナルへの寄稿記事

Nakahara, T, Kuroki, T, Ohta, E, Kajihata, T, Yamada, H, Yamanaka, M, Hashimoto, K, Tsutsumi, T, Hirano, M & Uchimura, H 2003, 'Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum', Parkinsonism and Related Disorders, 巻. 9, 番号 4, pp. 213-219. https://doi.org/10.1016/S1353-8020(02)00052-4
Nakahara, T. ; Kuroki, T. ; Ohta, E. ; Kajihata, T. ; Yamada, H. ; Yamanaka, M. ; Hashimoto, K. ; Tsutsumi, T. ; Hirano, M. ; Uchimura, H. / Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum. :: Parkinsonism and Related Disorders. 2003 ; 巻 9, 番号 4. pp. 213-219.
@article{b2a8ac9216654c7e87412416403fa6cf,
title = "Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum",
abstract = "We previously reported that haloperidol, a dopamine-D2 receptor antagonist, induced striatal expression of parkin gene, which mutations cause autosomal recessive juvenile parkinsonism. Because of an involvement of the parkin gene defect in selective degeneration of dopaminergic neurons, we herein examined the effect of the neurotoxic dose of methamphetamine (METH; 40mg/kg, i.p.) on gene expression of parkin and its substrate Pael-receptor (R) in the dopamine-rich areas of the rat brain, using reverse transcription-polymerase chain reaction. parkin mRNA levels in the striatum, but not in other regions, decreased at 1 and 2h and returned to the pre-drug basal levels at 4h after METH administration. METH also decreased Pael-R mRNA levels in the striatum and substantia nigra within 2h after METH, while haloperidol (2mg/kg, s.c.) increased Pael-R mRNA levels in the substantia nigra at 2h after administration. These results suggest that temporary suppression of gene expression of parkin and Pael-R may be associated with the METH-induced dopaminergic neurotoxicity. Taken together with our previous report, dopaminergic modulation of the expression of parkin and Pael-R genes in the nigro-striatal pathway may have significant implication for pathophysiology and treatment of parkinson disease.",
author = "T. Nakahara and T. Kuroki and E. Ohta and T. Kajihata and H. Yamada and M. Yamanaka and K. Hashimoto and T. Tsutsumi and M. Hirano and H. Uchimura",
year = "2003",
month = "3",
day = "1",
doi = "10.1016/S1353-8020(02)00052-4",
language = "English",
volume = "9",
pages = "213--219",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Effect of the neurotoxic dose of methamphetamine on gene expression of parkin and Pael-receptors in rat striatum

AU - Nakahara, T.

AU - Kuroki, T.

AU - Ohta, E.

AU - Kajihata, T.

AU - Yamada, H.

AU - Yamanaka, M.

AU - Hashimoto, K.

AU - Tsutsumi, T.

AU - Hirano, M.

AU - Uchimura, H.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - We previously reported that haloperidol, a dopamine-D2 receptor antagonist, induced striatal expression of parkin gene, which mutations cause autosomal recessive juvenile parkinsonism. Because of an involvement of the parkin gene defect in selective degeneration of dopaminergic neurons, we herein examined the effect of the neurotoxic dose of methamphetamine (METH; 40mg/kg, i.p.) on gene expression of parkin and its substrate Pael-receptor (R) in the dopamine-rich areas of the rat brain, using reverse transcription-polymerase chain reaction. parkin mRNA levels in the striatum, but not in other regions, decreased at 1 and 2h and returned to the pre-drug basal levels at 4h after METH administration. METH also decreased Pael-R mRNA levels in the striatum and substantia nigra within 2h after METH, while haloperidol (2mg/kg, s.c.) increased Pael-R mRNA levels in the substantia nigra at 2h after administration. These results suggest that temporary suppression of gene expression of parkin and Pael-R may be associated with the METH-induced dopaminergic neurotoxicity. Taken together with our previous report, dopaminergic modulation of the expression of parkin and Pael-R genes in the nigro-striatal pathway may have significant implication for pathophysiology and treatment of parkinson disease.

AB - We previously reported that haloperidol, a dopamine-D2 receptor antagonist, induced striatal expression of parkin gene, which mutations cause autosomal recessive juvenile parkinsonism. Because of an involvement of the parkin gene defect in selective degeneration of dopaminergic neurons, we herein examined the effect of the neurotoxic dose of methamphetamine (METH; 40mg/kg, i.p.) on gene expression of parkin and its substrate Pael-receptor (R) in the dopamine-rich areas of the rat brain, using reverse transcription-polymerase chain reaction. parkin mRNA levels in the striatum, but not in other regions, decreased at 1 and 2h and returned to the pre-drug basal levels at 4h after METH administration. METH also decreased Pael-R mRNA levels in the striatum and substantia nigra within 2h after METH, while haloperidol (2mg/kg, s.c.) increased Pael-R mRNA levels in the substantia nigra at 2h after administration. These results suggest that temporary suppression of gene expression of parkin and Pael-R may be associated with the METH-induced dopaminergic neurotoxicity. Taken together with our previous report, dopaminergic modulation of the expression of parkin and Pael-R genes in the nigro-striatal pathway may have significant implication for pathophysiology and treatment of parkinson disease.

UR - http://www.scopus.com/inward/record.url?scp=0037334558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037334558&partnerID=8YFLogxK

U2 - 10.1016/S1353-8020(02)00052-4

DO - 10.1016/S1353-8020(02)00052-4

M3 - Article

C2 - 12618056

AN - SCOPUS:0037334558

VL - 9

SP - 213

EP - 219

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 4

ER -